| Abstract: | ![]()
Rodent models for testing the efficacy of lead compounds are often invalidated by species selectivity of the compounds. The advent of mouse embryonic stem cell technology has allowed the development of genetically engineered mouse strains that incorporate a specific human gene in place of the orthologous mouse gene, a so‐called knock‐in mouse. This study describes the generation and validation of a mutant mouse line that expresses human CCR2B as a functional substitute for murine CCR2. The human CCR2B knock‐in mice are viable and appear normal. In vitro assays indicate that the CCR2B knock‐in is functionally expressed, giving a macrophage chemotactic profile in response to JE or MCP‐1 that is similar to human peripheral blood monocytes rather than that of a murine macrophage cell line. In addition, the human selective CCR2B antagonist, SB‐399721, was a more potent inhibitor of CCR2B knock‐in macrophages in response to hMCP‐1 than JE. The ability of the human CCR2B gene to functionally substitute for the mouse orthologue in vivo is demonstrated by a normal inflammatory response to intraperitoneal thioglycollate injection. Drug Dev. Res. 55:197–209, 2002. © 2002 Wiley‐Liss, Inc. |
